Novo Nordisk A/S Says Victoza Superior to Amylin Pharmaceuticals, Inc. Rival

The world’s largest insulin maker Novo Nordisk A/S (NOVO-B.KO) said late Sunday fresh study results show that its diabetes 2-treating drug Victoza more efficiently lowers blood sugar levels and helps patients lose weight than key competitors’ drugs. According to the “real world” study, which is based on the treatment of 1,114 British diabetes patients, the use of Victoza resulted in a greater reduction in average blood sugar levels than U.S. peer Amylin Pharmaceuticals Inc.'s (AMLN) diabetes drug Byetta or dipeptidyl peptidase 4 inhibitors, a group of oral antidiabetes drugs.